The research was led by Professor Shigenobu Matsumura of Osaka Metropolitan University’s Graduate School of Human Life and Ecology. The team focused on neurons that express melanocortin-4 receptor, commonly known as MC4R. These neurons are located in the hypothalamus, a brain region that coordinates appetite, energy expenditure, body weight, temperature, and several other physiological functions. MC4R signaling is one of the central pathways involved in controlling body mass. When activated, it generally reduces food intake and promotes a state of greater energy use. Genetic or functional disturbances in this pathway have been associated with severe forms of obesity in both humans and experimental animals.

OPA1 is a protein found within mitochondria, the structures often described as the energy-producing units of cells. More specifically, OPA1 helps mitochondria maintain their internal architecture by promoting the fusion of mitochondrial membranes. This structural organization is essential for efficient energy production, regulation of cellular stress, and communication between metabolic pathways. Neurons have particularly high energy demands because they must maintain electrical gradients and continuously transmit signals. If mitochondrial function is impaired in appetite-regulating neurons, the resulting metabolic disturbance could alter how the brain interprets nutritional signals and controls feeding behavior.

To investigate that possibility, the researchers compared normal mice with genetically modified animals lacking OPA1 specifically in MC4R-expressing neurons. This neuron-specific approach allowed the team to examine the protein’s role in appetite regulation without eliminating OPA1 throughout the body, where it performs essential functions in many tissues. The animals were allowed to feed freely, and soybean oil was used as a dietary fat source. Rather than testing only a rigid, pre-measured diet, the free-feeding design enabled the researchers to observe how the mice voluntarily responded when fat was available as part of their food environment.

The results revealed a notable difference between male and female mice. In male wild-type animals, soybean oil increased the expression of OPA1, suggesting that dietary fat may trigger a mitochondrial adaptation in MC4R neurons. That response was not observed in females. The sex-specific pattern indicates that the neurons may process the metabolic consequences of dietary fat differently depending on biological sex. The researchers did not present the finding as evidence that OPA1 alone determines obesity, but it points to the protein as one component of a broader network connecting food composition, mitochondrial activity, neural signaling, and long-term body-weight regulation.

The consequences of removing OPA1 were especially striking over time. Mice without OPA1 in their MC4R neurons consumed more food and developed age-related weight gain, with obesity becoming more apparent as the animals grew older. When given access to both standard chow and soybean oil, the modified mice consumed more fat and gained additional weight. The effect was particularly pronounced in females, even though female wild-type mice did not show the same soybean-oil-associated increase in OPA1 expression seen in males. This apparent mismatch suggests that the absence of OPA1 may expose a vulnerability in female appetite-control circuits rather than simply preventing a protective response that occurs in males.

At the cellular level, the findings are consistent with the idea that mitochondria do more than supply energy. They also act as sensors and regulators of cellular conditions. Changes in mitochondrial fusion can influence the production of energy, reactive oxygen species, calcium handling, and the ability of neurons to respond to hormonal and nutrient-related signals. In MC4R neurons, such changes could affect the strength or timing of melanocortin signaling, potentially making the brain less effective at limiting food intake after energy needs have been met. The current study does not establish every step in that chain, but it provides experimental evidence that mitochondrial integrity within a defined neuronal population is linked to dietary-fat consumption and body-weight control.

The researchers also tested setmelanotide, a drug that activates MC4R and is used to treat certain forms of genetic obesity. In control male mice, the compound successfully suppressed appetite. It also reduced food intake in male mice lacking OPA1. In females, however, the appetite-suppressing effect was significantly weaker when OPA1 was absent from MC4R neurons. This result is important because it suggests that the effectiveness of an MC4R-targeting treatment may depend not only on whether the receptor is present, but also on the metabolic condition of the neurons that contain it. A receptor-activating drug may be less effective if the cellular machinery needed to translate that signal into sustained appetite control has been disrupted.

The study was conducted in mice, so its findings cannot yet be assumed to apply directly to people. Human appetite regulation involves numerous interacting systems, including hormones released by the gut and adipose tissue, reward pathways involved in food preference, sleep, stress, physical activity, and environmental access to calorie-dense foods. Soybean oil was also used as an experimental fat source and should not be interpreted as the sole cause of obesity in humans. Nevertheless, the work adds to growing evidence that dietary fat can influence the brain through mechanisms that extend beyond calorie intake alone. By identifying a link between OPA1, MC4R neurons, and sex-dependent responses to fat, the researchers provide a potential molecular target for future studies of personalized obesity therapies.

“Our findings provide key insights into the mechanisms underlying obesity from the perspective of neuronal energy metabolism,” Matsumura said. He added that the observed differences in OPA1 responses and obesity susceptibility could help guide treatments that account for sex-specific biology. Future research will need to determine how OPA1 is regulated in human appetite circuits, whether similar changes occur in people with obesity, and how mitochondrial dynamics interact with hormones and other signals that activate MC4R. The findings, published in The FASEB Journal, suggest that the battle against overeating may depend partly on the condition of microscopic energy systems inside the brain’s appetite-control neurons.

Subject of Research: Animals

Article Title: OPA1 in MC4R Neurons Regulates Dietary Fat Intake and Body Weight in Mice

News Publication Date: 21-May-2026

Web References: Osaka Metropolitan University, https://www.omu.ac.jp/en/

References: DOI: 10.1096/fj.202600452R

Image Credits: Osaka Metropolitan University

Keywords

OPA1, MC4R neurons, obesity, dietary fat, soybean oil, appetite regulation, mitochondria, hypothalamus, setmelanotide, body weight, sex differences, mice

Obesity and type 2 diabetes mellitus (T2DM) are rapidly escalating global health crises, representing intertwined metabolic derangements with devastating consequences. Despite extensive research, the molecular underpinnings that bridge adiposity and insulin resistance remain incompletely understood, particularly regarding how endothelial dysfunction exacerbates metabolic disarray. The present work illuminates the endothelial mitochondrial protein FUNDC1 as a linchpin orchestrating metabolic reprogramming by modulating SIRT3 activity, a key deacetylase known for its role in maintaining mitochondrial integrity and oxidative metabolism.

The team began by profiling endothelial cell metabolism in murine models of diet-induced obesity, noting a marked downregulation of FUNDC1 expression correlating with impaired mitochondrial function and heightened oxidative stress. Through a series of meticulous in vivo and in vitro experiments, the researchers demonstrated that FUNDC1 deficiency disrupts the activity of SIRT3, leading to the aberrant acetylation and dysregulation of metabolic enzymes. This loss of mitochondrial homeostasis culminates in a metabolic shift favoring glycolysis over oxidative phosphorylation, a hallmark of endothelial dysfunction.

Interestingly, FUNDC1’s influence extends beyond mitochondrial mechanics; the study reveals that FUNDC1 modulates the transcription factor GATA2, which orchestrates endothelin-1 expression, a potent vasoactive peptide. Elevated endothelin-1 levels were observed in endothelial cells lacking functional FUNDC1, driving vascular inflammation, impaired vasodilation, and systemic metabolic effects that promote insulin resistance. This SIRT3/GATA2/endothelin-1 axis thus emerges as a critical conduit linking endothelial mitochondrial health to the systemic metabolic alterations seen in obesity progressing toward diabetes.

Perhaps the most compelling aspect of this study is the demonstration that restoring FUNDC1 function in endothelial cells can reverse the deleterious metabolic shifts. Gene therapy approaches in obese diabetic mouse models reinstated FUNDC1 expression, normalized SIRT3 activity, and curtailed endothelin-1 overproduction, significantly improving glucose tolerance and insulin sensitivity. These findings suggest that targeting endothelial FUNDC1 could be a viable strategy to prevent or treat T2DM by disrupting the vicious cycle of endothelial dysfunction and metabolic reprogramming.

This research also delves deeply into the molecular mechanisms governing the cross-talk between mitochondrial dynamics and nuclear gene expression within endothelial cells. FUNDC1, traditionally known for its role in mitophagy, appears to exert a previously unappreciated influence on transcriptional regulation by modulating GATA2. Through intricate signaling cascades, endothelial mitochondria signal metabolic status changes to the nucleus, adjusting gene expression profiles that modulate vascular tone and inflammation, thereby impacting systemic metabolism.

The study employed state-of-the-art metabolomic and transcriptomic analyses to dissect these pathways, revealing a comprehensive map of endothelial metabolic reprogramming events induced by FUNDC1 perturbations. The resultant data highlight alterations in fatty acid oxidation, reactive oxygen species generation, and nitric oxide bioavailability—key parameters that govern endothelial cell function and ultimately dictate metabolic homeostasis in peripheral tissues.

Moreover, the team explored how chronic high-fat diet exposure disrupts this FUNDC1-mediated regulatory axis, emphasizing the role of environmental and lifestyle factors in precipitating endothelial dysfunction. The interplay between nutrient excess and mitochondrial compromise in endothelial cells represents a critical nexus where metabolic disease takes root, underscoring the importance of preserving mitochondrial quality control mechanisms for vascular and systemic health.

Beyond providing mechanistic insights, the study’s translational implications are profound. The identification of the FUNDC1/SIRT3/GATA2/endothelin-1 axis as a driver of obesity-diabetes transition reveals new molecular targets for drug development. Agents that can enhance FUNDC1 expression or mimic its effects could revolutionize therapeutic approaches aimed at restoring endothelial function and metabolic balance, offering hope to millions affected by metabolic syndrome and diabetes worldwide.

The multidisciplinary approach combining molecular biology, genetics, metabolism, and vascular physiology highlights the complexity of the metabolic network controlling energy homeostasis. By centering on endothelial mitochondria, this research shifts focus from classical adipocentric or pancreatic beta-cell paradigms to the vascular interface as a critical determinant of disease progression, opening novel research avenues that integrate vascular and metabolic health.

Furthermore, these findings resonate beyond diabetes research, implicating endothelial mitochondrial dysfunction in a spectrum of cardiometabolic diseases. The conserved nature of the identified pathways suggests that endothelial FUNDC1 may modulate systemic pathologies such as atherosclerosis, hypertension, and chronic inflammation, thereby broadening the horizon for vascular-targeted therapies.

In conclusion, the study by Li, J., Li, D., Zhao, F., et al. marks a significant milestone in unraveling the endothelial contributions to metabolic disease. The elucidation of the FUNDC1-regulated SIRT3/GATA2/endothelin-1 signaling axis provides a novel and mechanistically rich framework for understanding the pathogenesis of the obesity-diabetes continuum. As obesity rates continue to climb globally, these insights offer a beacon of hope toward innovative interventions that target the vascular-metabolic interface, promising improved outcomes for patients burdened by these chronic conditions.

Future research directions emerging from this work include detailed mapping of FUNDC1 interactions within mitochondrial and nuclear compartments, exploration of its regulatory dynamics under varied metabolic stresses, and development of endothelial-specific delivery systems for FUNDC1 modulators. Such endeavors will be critical to translate these foundational discoveries into therapeutics capable of altering the course of diabetes and its associated complications.

This study exemplifies the power of integrative biomedical research to challenge existing dogmas and propel the understanding of complex diseases. The endothelium, long viewed solely as a passive barrier, is now revealed as an active metabolic organ capable of reshaping cellular and systemic physiology through mitochondrial signaling pathways. Targeting these novel molecular axes holds the promise of transformative advances in the prevention and treatment of metabolic diseases in the coming decade.

Subject of Research: Endothelial mitochondrial regulation in metabolic reprogramming and the obesity-to-diabetes transition

Article Title: Endothelial FUNDC1 regulates metabolic reprogramming and the obesity-diabetes transition through the SIRT3/GATA2/endothelin-1 axis

Article References:
Li, J., Li, D., Zhao, F. et al. Endothelial FUNDC1 regulates metabolic reprogramming and the obesity-diabetes transition through the SIRT3/GATA2/endothelin-1 axis. Nat Commun (2026). https://doi.org/10.1038/s41467-026-68548-4

Image Credits: AI Generated